References
- Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926-32
- Baccarani M, Deininger M, Rosti G, et al. European LeukemiaNet recommendations for the Management of Chronic Myeloid Leukemia: 2013. Blood 2013;122:872-84
- Network NCC. Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia (v 4.2013). 2013. http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed 4 Sep 2013
- Chen L, Guérin A, Xie J, et al. Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis. Curr Med Res Opin 2012;28:1831-9. http://www.ncbi.nlm.nih.gov/pubmed/23127201. Accessed 4 Sep 2013
- Goldberg SL, Chen L, Guerin A, et al. Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Curr Med Res Opin 2013;29:1075-82. http://www.ncbi.nlm.nih.gov/pubmed/23738923. Accessed 4 Sep 2013 September 4, 2013
- Pasquini R, Cortes JE, Kantarjian HM, et al. Paper: survey of the frontline treatment and management of Chronic Myeloid Leukemia (CML) in a real-word setting: The 3rd Annual Update of the Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukem. In: 53rd ASH Annual Meeting and Exposition. San Diego, CA; 2011. https://ash.confex.com/ash/2011/webprogram/Paper40024.html. Accessed 4 Sep 2013
- Bollu V, Quintas-Cardama A, Flamm M, et al. Resource utilization and perceptions of major molecular response in chronic myeloid leukemia (CML): results of a Delphi panel study. Value Health 2011;14:A156-A157
- De Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol Official J Am Soc Clin Oncol 2008;26:3358-63. http://www.ncbi.nlm.nih.gov/pubmed/18519952. Accessed 4 Sep 2013
- Corporation NP. Gleevec™ (imatinib mesylate) (drug label). 2003. http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021588lbl.pdf. Accessed 4 Sep 2013
- Corporation NP. Tasigna® (nilotinib) Capsules (drug label). 2007. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022068lbl.pdf. Accessed 4 Sep 2013
- Company B-MS. SPRYCEL™ (dasatinib) Tablets (drug label). 2007. http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021986lbl.pdf. Accessed 4 Sep 2013
- Pharmaceuticals A. ICLUSIG® (ponatinib) tablets (drug label). 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf. Accessed 4 Sep 2013
- USA TP. SYNRIBO™ (omacetaxine mepesuccinate) for Injection (drug label). 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf. Accessed 4 Sep 2013
- Inc. P. BOSULIF® (bosutinib) tablets (drug label). 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf. Accessed 4 Sep 2013
- Jain P, Kantarjian H, Cortes J. Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Opt Oncol 2013;14:127-43. http://www.ncbi.nlm.nih.gov/pubmed/23572291. Accessed 4 Sep 2013
- Redaelli A, Stephens JM, Laskin BL, et al. The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML. Exp Rev Anticancer Ther 2003;3:311-29. http://www.ncbi.nlm.nih.gov/pubmed/12820775. Accessed 4 Sep 2013
- Martinelli G, Iacobucci I, Soverini S, et al. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. Hematol Oncol 2006;24:196-204. http://www.ncbi.nlm.nih.gov/pubmed/16988930. Accessed 4 Sep 2013
- Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res Official J Am Assoc Cancer Res 2007;13:6136-43. http://clincancerres.aacrjournals.org/content/13/20/6136.short. Accessed 4 Sep 2013
- Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chr. J Clin Oncol Official J Am Soc Clin Oncol 2005;23:4100-9. http://jco.ascopubs.org/content/23/18/4100.short. Accessed 4 Sep 2013
- Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. PharmacoEconomics 2007;25:481-96
- Wu EQ, Guerin A, Yu AP, et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010;26:2861-9. http://www.ncbi.nlm.nih.gov/pubmed/21062136. Accessed 4 Sep 2013
- Guérin A, Chen L, Wu EQ, et al. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin 2012;28:1155-62. http://www.ncbi.nlm.nih.gov/pubmed/22738777. Accessed 4 Sep 2013
- Guérin A, Wu EQ, Bollu VK, et al. The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Med Econ 2013;16:125-33. http://www.ncbi.nlm.nih.gov/pubmed/22587385. Accessed 4 Sep 2013
- Elixhauser A, Steiner C, Kruzikas D. Comorbidity Software Documentation. 2004. HCUP Methods Series Report # 2004-1. ONLINE February 6, 2004. U.S. Agency for Healthcare Research and Quality. Available: http://www.hcupus.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp. Accessed 4 Sep 2013
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9. http://www.ncbi.nlm.nih.gov/pubmed/16224307. Accessed 4 Sep 2013
- Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 2000;29:891-8